Zila Names New CFO

PHOENIX--(BUSINESS WIRE)--Feb. 24, 2003--Zila, Inc. (Nasdaq:ZILA), announced today the appointment of Lawrence J. Batina, a graduate of Harvard Business School with extensive financial and senior management experience, as its new Chief Financial Officer and Secretary, effective February 24, 2003.

Batina, 50 years old, will be responsible for all financial management activities at Zila, an international provider of healthcare and biotechnology products for dental/medical professionals and consumers. He succeeds David Petulla, who was interim CFO and will remain at Zila as Director of Finance.

For the last five years, Batina was CFO of Naturade, Inc., a California-based marketer of nutraceutical products sold in more than 35,000 mass-market and health food stores. He previously served in various financial and accounting capacities that were principally in the food products industry, following five years in public accounting with KPMG. Batina holds an M.B.A. from Harvard Business School and a B.S. in Business Administration from the University of California-Berkeley, and is a Certified Public Accountant.

Douglas Burkett, Ph.D., chairman, CEO and president of Zila, said Batina's expertise and financial and operational background make him the ideal executive to execute Zila's new financial strategy.

"I expect Larry Batina to work closely with our Board of Directors, management team and me to help Zila achieve its goals of growth and financial strength, while finalizing the financial plan that will help lead us toward FDA approval and marketing of our OraTest(R) cancer diagnostic product," Dr. Burkett said. "He also shares our commitment to complete, clear and concise financial reporting, a hallmark of our dedication to integrity throughout the business."

Batina said that he is looking forward to joining the talented, energetic and aggressive new management team that Dr. Burkett has assembled at Zila.

"I'm very impressed with Zila's new management and Board, and the focus, drive, and enthusiasm of the entire team," Batina said. "I'm eager to contribute my experience and financial knowledge to help achieve Zila's operational and strategic objectives."

Zila said it expects to report financial results in mid-March for its second fiscal quarter, which ended January 31, 2003. In the next few weeks, Zila will set and announce the date and time of the conference call to discuss those results with investors.

About Zila

Zila, Inc., headquartered in Phoenix, is an international provider of healthcare and biotechnology products for dental/medical professionals and consumers. Zila has three business units:

Zila Pharmaceuticals, "The Oral Soft Tissue Experts" marketing Zilactin(R) OTC oral care products, Peridex(R) prescription periodontal rinse and ViziLite(TM) examination kits

Zila Nutraceuticals, manufacturer and marketer of Ester-C(R), a branded, superior efficacy nutrition product

Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection through its patented OraTest(R) and Zila(R) Tolonium Chloride technologies

For more information about Zila, visit www.zila.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K and 10-K/A for its fiscal year ended July 31, 2002, and its Form 10-Q for the quarter ended October 31, 2002, filed with the Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.